{"id":"comparator-antidiabetic-standard-of-care","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5966370","moleculeType":null,"molecularWeight":"399.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a comparator standard of care, this represents the established antidiabetic treatment regimen (typically metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 agonists, insulin, or combinations thereof) against which investigational antidiabetic agents are evaluated. The specific mechanism depends on which standard-of-care agents are included in the comparator arm for a given trial.","oneSentence":"This is a comparator arm representing standard-of-care antidiabetic therapy used as a control reference in clinical trials, not a specific drug with a single mechanism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:06:57.171Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus (as standard-of-care comparator in phase 3 trials)"}]},"trialDetails":[{"nctId":"NCT07444203","phase":"","title":"Transformative Research in Diabetic Nephropathy 2.0","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-11-12","conditions":"Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic","enrollment":200},{"nctId":"NCT02488252","phase":"PHASE2, PHASE3","title":"Semi-individualised Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2015-07","conditions":"Diabetic Nephropathies","enrollment":148},{"nctId":"NCT03535935","phase":"PHASE2, PHASE3","title":"Efficacy, Safety and Response Predictors of Adjuvant Astragalus Therapy for Diabetic Kidney Disease","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2018-07-01","conditions":"Diabetic Nephropathies, Diabetic Kidney Disease","enrollment":118},{"nctId":"NCT03640221","phase":"PHASE4","title":"Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.","status":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-01","conditions":"Hypertension, Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT00875394","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-02-01","conditions":"Diabetes Mellitus, Non-Insulin-Dependent","enrollment":68}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Comparator: Antidiabetic Standard of Care","genericName":"Comparator: Antidiabetic Standard of Care","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a comparator arm representing standard-of-care antidiabetic therapy used as a control reference in clinical trials, not a specific drug with a single mechanism. Used for Type 2 diabetes mellitus (as standard-of-care comparator in phase 3 trials).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}